A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Starting in Jerusalem, he then moves with his team of viruses as clandestine passengers in migrating birds to Europe and the USA. The coronavirus family discusses in their periodic meetings the foolish reaction of the surprised leaders of those nations, and raises doubts about the efficiency and the value of their new vaccines against the variants and mutations that the viruses create with nonchalance and ease. Toward the end of the saga the wise Virionette surprises everybody with a new idea thinking outside the box. This is the tale of the Coronavirus from an unconventional point of view, whose purpose is to educate children and adolescents about how viruses work and ultimately – how to rid ourselves of them. "Waiting for the Coronavirus in the Kingdom of PAMONA"' a book published through Partridge Singapore August 2021 After a long pause the king said, 'Tell me, how can we be different from all the other countries hit by the pandemic, whose morbidity and mortality rates are so frighteningly high? How can we think differently, how should we be thinking Dean-el wrote that to overcome the viral epidemics that will be visiting upon us in the future, we have to develop a nature-based vaccine composed of what he called nano-Yaho' particles and turn them into effective and safe method to defeat all kinds of viruses. This is a tale told by the ancient Pamonan people who left the Middle East and settled in the f Indonesian archipelago, founded a prosperous kingdom and faced the coronavirus pandemic that spread from China.
In 2024, Lawrence Berkeley National Laboratory published a reliable way to make element 116, livermorium, using a titanium beam to irradiate a plutonium foil. This method may be useful in producing several more elements beyond Oganesson, element 118.
The VITAL-H study will evaluate the effectiveness of rapamycin, dapagliflozin, and semaglutide in generally healthy adults between the ages of 60 and 65, using innovative measures of intrinsic capacity and healthspan rather than traditional disease-specific endpoints. This groundbreaking study represents one of the first large-scale clinical trials specifically designed to target aging itself as a modifiable biological process, with the long-term goal of delaying the development of multiple chronic diseases simultaneously and extending years of healthy, independent living. The ARPA-H PROSPR award positions the Barshop Institute as a national leader in the emerging field of gerotherapeutics and establishes one of the largest federally funded clinical research programs dedicated to healthy longevity in the United States. Beyond evaluating promising interventions, the program is expected to establish new clinical trial methodologies, validate biomarkers and measures of biological aging, and provide a regulatory framework for future healthspan-focused therapeutics. Through collaborations with academic institutions, healthcare systems, and industry partners across the country, the Institute is helping build the scientific foundation necessary for future preventive therapies that target aging as the common biological driver of many chronic diseases.
=== 1870s === 1869/1870: American beekeeper Ellen Smith Tupper became the first female editor of an entomological journal. 1870: Katharine Murray Lyell was a British botanist, author of an early book on the worldwide distribution of ferns, and editor of volumes of the correspondence of several of the era's notable scientists. 1870: American engineer and chemist Ellen Swallow Richards became the first American woman to earn a degree in chemistry. 1870: Russian chemist Anna Volkova became the first female member of the Russian Chemical Society. 1874: Russian chemist Julia Lermontova became the first Russian woman to receive a PhD in chemistry. 1875: Hungarian archaeologist Zsófia Torma excavated the site of Turdaș-Luncă in Hunedoara County, today in Romania. The site, which uncovered valuable prehistoric artifacts, became one of the most important archaeological discoveries in Europe. 1876–1878: American naturalist Mary Treat studied insectivorous plants in Florida. Her contributions to the scientific understanding of how these plants caught and digested prey were acknowledged by Charles Darwin and Asa Gray. 1878: English entomologist Eleanor Anne Ormerod became the first female Fellow of the Royal Meteorological Society. A few years afterwards, she was appointed as Consulting Entomologist to the Royal Agricultural Society.
Sources: en.wikipedia.org
On Colombia's Caribbean coast, tajadas of fried green plantain are consumed along with grilled meats, and are the dietary equivalent of the French-fried potatoes/chips of Europe and North America. After removing the skin, maduro can be sliced (between 3 and 20 mm or 1⁄8–25⁄32 in thick) and pan-fried in oil until golden brown or according to preference. In the Dominican Republic, Ecuador, Colombia, Honduras (where they are usually eaten with the native sour cream) and Venezuela, they are also eaten baked in the oven (sometimes with cinnamon). In Puerto Rico baked plátanos maduros are usually eaten for breakfast and served with eggs (mainly an omelet with cheese), chorizo or bacon. Only salt is added to green plantains. Tacacho is a roasted plantain Amazonian cuisine dish from Peru. It is usually served con cecina, with bits of pork. In Venezuela, a yo-yo is a traditional dish made of two short slices of fried ripened plantain (see Tajada) placed on top of each other, with local soft white cheese in the middle (in a sandwich-like fashion) and held together with toothpicks. The arrangement is dipped in beaten eggs and fried again until the cheese melts and the yo-yo acquires a deep golden hue. They are served as sides or entrees. In Puerto Rico fried plantains are served in a variety of ways as side dishes, fast foods, and main course. An alternative to tostones are arañitas (little spiders). The name comes from the grated green and yellow plantain pieces forming little legs that stick out of the fritter itself, which ends up looking like a prickly spider on a plate.
Bornholm disease, also known as epidemic pleurodynia, is a condition characterized by myositis of the abdomen or chest caused by the Coxsackie B virus or other viruses. The myositis manifests as an intermittent stabbing pain in the musculature that is seen primarily in children and young adults. It is named after the Danish island of Bornholm in the Baltic Sea where an outbreak was one of the first to be described.
=== Head of intelligence === Noriega proved to be a very capable head of intelligence. During his tenure, he exiled 1,300 Panamanians whom he viewed as threats to the government. He also kept files on several officials within the military, the government, and the judiciary, allowing him to blackmail them later. Noriega also held the positions of head of the political police and head of immigration. His tenure was marked by intimidation and harassment of opposition parties and their leaders. He was described as doing much of Torrijos's "dirty work". For instance, Noriega ordered the death of Jesús Héctor Gallego Herrera, a priest whose work at an agricultural cooperative was seen as a threat by the government. Gallego's body is reported to have been thrown from a helicopter into the sea. He also made an effort during this period to portray Panama as a hub of enforcement against drug smuggling, possibly as a result of pressure from Torrijos. By the early 1970s, American law enforcement officials had reports of Noriega's possible involvement with narcotics trafficking. No formal criminal investigations were begun, and no indictment was brought: according to Dinges, this was due to the potential diplomatic consequences. This evidence included the testimony of an arrested boat courier, and of a drug smuggler arrested in New York. Though Torrijos frequently promised the U.S. cooperation in dealing with drug smuggling, Noriega would have headed any effort at enforcement, and the U.S. began to see Noriega as an obstacle to combatting drug smuggling. Dinges writes that the U.S.
== See also == Amnesic shellfish poisoning Diarrheal shellfish poisoning Neurotoxic shellfish poisoning Harmful algal blooms (see "toxins") Ciguatera Fugu Cyanotoxin Dinoflagellate ecology and physiology (see "neurotoxins", "red tide", and "phosphate") Red tide crisis in Chiloé
Most of these exacerbations were mild to moderately severe and developed more often in patients who were older in age or had generalized myasthenia gravis, myasthenia gravis with bulbar symptoms, severe symptoms, a thymoma, or a history of thymectomy to remove a thymoma. These studies, however, were mostly of low quality. Prospective studies comparing the effects of the different corticosteroids to define the rate and severity of the myasthenia exacerbations are needed. Calcium channel blockers: Calcium channel blockers (e.g., felodipine, nifedipine, and verapamil) are drugs that lower blood pressure in people with hypertension. Felodipine and nifedipine are reported to worsen myasthenia gravis and nifedipine and verapamil are reported to cause respiratory failure in people with severe generalized myasthenia gravis. Penicillamine: Penicillamine is a chelation therapy drug used to treat various diseases (e.g., Wilson's disease). About 1-2% of individuals treated long term with penicillamine develop myasthenia gravis and/or develop low concentrations of antibodies to AChR. Their myasthenia gravis is often mild and predominantly ocular myasthenia gravis, becomes evident usually 6–7 months (range one month to 8 years) after starting the drug, and goes into complete remission in 70% of the cases within 6–10 months after discontinuing the drug. Botulinum toxin A: Botulinum toxin A (sold under the brand name Botox, Jeuveau, and Xeomin) blocks transmission at neuromuscular junctions to paralyze the muscles into which it is injected.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.